Effect of duloxetine and vitamin B12 on pain and numbness with chemotherapy-induced neuropathy

Effect of duloxetine and vitamin B12 on pain and numbness with chemotherapy-induced neuropathy - duloxetine on chemotherapy-induced neuropathy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011554

Enrollment

Registered

2013-08-22

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

one week duloxetine 20mg/day (loading dose), three weeks duloxetine 40 mg /day, 2~4 weeks washout period and four weeks vitamin 12 1500mg/day reverse order

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who were administered vincristine, paclitaxel, docetaxel, bortezomib or oxaliplatine and feel neuropathic pain or numbness (in or outpatients)

Exclusion criteria

Exclusion criteria: 1) bad controlled liver, kidney, heart, lung , hypertension and infectious diseases 2) psychiatric diseases including depression 3) pregnancy or breast-feeding 4) intake MAO inhibitor (contraindication with duloxetine) 5) the cases whom the doctor decide not to be the indication

Design outcomes

Primary

Measure	Time frame
numbness and pain (VAS)	—

Secondary

Measure	Time frame
neurological symptoms (CTCAE)	—

Countries

Japan

Contacts

Public ContactYasuo Hirayama

Higashi Sapporo Hospital Department of Hematology/Oncology

hirayama@hsh.or.jp011-812-2311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026